|
|
Position:
Director of Business Development
Employer:
Simcere of America Inc.
Description:
• Working with Scouts and be responsible for in-depth evaluation and prioritization of external opportunities
|
for collaborations, partnerships, in-licensing, structured transactions and acquisitions • Lead cross-functional due diligence team to assess external products and programs (Executive, R&D, Sales & Marketing, Finance, Legal, Regulatory, Manufacturing, etc.)
|
-
Be responsible for financial modeling of different types of deals, including in-licensing, partnerships, collaborations, acquisitions. Identify key assumptions and risks and incorporate inputs from different teams, R&D, clinical, commercial and legal.
-
Be responsible for drafting term sheets for different types of deals and lead business negotiations.
-
Be responsible for making proposals and presenting to the management team.
-
Represent Simcere at industry, investor and partnering conferences; develop and maintain the relationship with a wide range of pharmaceutical/biotechnology industry participants.
|
Qualifications/Experience:
-
Bachelor’s degree in science at minimum; MBA, MD, JD, PhD is strongly preferred
-
6+ years’ experience in business development, consulting or investment banking
-
Strong analytical skills, knowledge of financial modeling, including DCF, NPV analysis is required
-
Familiarity with forecasting methodologies is preferred
-
Familiarity with drug development and commercialization is a plus
-
Strong communication and presentation skills
-
Strong leadership to lead and work with cross-functional team
-
Flexibility to travel domestically and internationally 20-30%
-
Demonstrated ability to work in a complex matrix and cross-cultural environment
-
Ability to excel in demanding and fast-paced working environment
-
Mandarin speaking is a plus
Location:
Boston, USA or Japan, Europe (London)
Contact:
Chen Chen (chen.chen@simcereusa.com)
Post Date:
11/6/2018 2:10:33 PM
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Submit a Text Ad
|